January 28, 2026: Washington, DC: In advance of a Senate Commerce subcommittee hearing on reform in the live event industry, the National Consumers League urged leaders in the U.S. Senate to prioritize passing the bipartisan TICKET Act (S. 281/H.R. 1402), which has already overwhelmingly passed the U.S. House of Representatives and the Senate Commerce Committee.
January 26, 2026: “American exceptionalism,” the idea that the United States is a unique nation rooted in democracy and liberty, dates back to the country’s founding. In fact, the colonial writer Thomas Paine described America as an exceptional civilization in his 1776 pamphlet Common Sense.
January 10, 2026: Washington, DC – Today, the National Consumers League’s (NCL) Child Labor Coalition (CLC) is proud to support Congresswoman Hillary Scholten’s reintroduction of her bipartisan Justice for Exploited Children Act alongside Congressman Ryan Mackenzie (PA-07). This legislation would increase both civil and criminal penalties for companies that violate child labor standards established in the Fair Labor Standards Act. Under current law, penalties for child labor violations are as low as $10,000 in some cases – and the maximum prison sentence is 6 months, even if violations result in the death or serious injury of a child.
January 7, 2026: Washington, DC – As a voice for the nation’s consumers, the National Consumers League (NCL) values recommendations in the newly released Dietary Guidelines for Americans, 2025–2030 that encourage consumers to eat more fruits, vegetables, and whole grains but has significant concerns that the guidelines abandon science-based recommendations limiting daily consumption of red meat, full-fat dairy products, and alcoholic beverages.
January 6, 2026: Washington, DC – The National Consumers League strongly opposes the decision to reduce the CDC’s recommended childhood immunization schedule without scientific justification or public review.
January 5, 2026: Washington, DC – The National Consumers League applauds Mayor Mamdani and the New York City Department of Consumer and Worker Protection for taking bold executive action to combat hidden junk fees, subscription tricks, and traps.
December 16, 2025: Washington, DC – The National Consumers League (NCL), joined by 29 nonprofit, consumer, civil rights, faith-based, and civic organizations, urged congressional leaders to reject H.R. 5179, the District of Columbia Attorney General Appointment Reform Act, today. The organizations warn that the bill would dangerously undermine the independence of the District’s chief law enforcement office and expose nonprofits and consumers to politicized enforcement.
December 12, 2025: Washington, DC – Yesterday, in an Executive Order, President Trump directed his administration to block state-enacted safeguards around artificial intelligence, including the restriction of federal funding to states the White House targets and the creation of a “Litigation Task Force” to challenge states’ consumer protections. NCL wholly opposes these efforts as unregulated AI products create significant risks to the public, from serious issues regarding safety and mental health, to unauthorized uses of consumer data and creative works.
December 8, 2025: When cities crack down on short-term rentals, the headlines often scream “Airbnb vs. Hotels!” — but the story is bigger than a platform feud. Behind the zoning rules and permit limits lies a high-stakes battle over who gets to control the lodging market, and whether “consumer protection” is just a cover for keeping competition out. A recent lawsuit in the Deep South may seem local, but it highlights a national trend with real consequences for travelers, homeowners, and communities alike.
December 5, 2025: Washington, DC – The National Consumers League (NCL) is deeply concerned by today’s vote from the CDC’s Advisory Committee on Immunization Practices (ACIP) to eliminate the long-standing recommendation that all newborns receive a hepatitis B vaccine at birth.
The work of the National Consumers League is making a difference in people’s lives across the country. Meet some of the consumers touched by our programs.
Read about NCL’s impact
Paige, 55, a Nashville wife and mother of two, answered an employment ad for secret shoppers. Before sending payment to the scammers, she reached out to NCL.
Read about NCL’s impact
A grease fire flared up in Decklan’s kitchen. As his family scrambled and panicked, fearing that the whole house might erupt in flames, Decklan remained calm. He hurried over to the pantry, grabbed some baking soda, and dumped it on the fire quickly extinguishing the blaze.
Read about NCL’s impact
Cincinnati resident Charles, 45, lost his computer business — and health insurance— during a time of economic downturn. A diabetic, Charles was now unable to afford his medication. He stopped taking it which made him seriously ill and put his life at risk.
Read about NCL’s impact
Jeremy is a fast-food worker who has been employed at a number of Chipotle restaurants in New York City. When he was just 20 years old, he took part in an NCL research project that revealed that management practices within the fast food chain were putting workers—and food safety for customers—at risk.
Read about NCL’s impact
By Sally Greenberg, NCL Executive Director
While the COVID-19 pandemic has led to hardship for all Americans, it is clear that people of color have been disproportionately burdened. Across the health care continuum, addressing this disparity has become part of the broader conversation about the history of systemic racism and the underlying social determinants of health that negatively affect the mental, physical, and economic health of individuals and entire communities.
The pandemic has underscored persistent health disparities, and there is growing recognition that representation in research and clinical trials can have a profound impact on health outcomes. A lack of representation from racially and ethnically diverse groups in research and clinical trials have typically led to gaps in data, missing the opportunity to assess the full impact of various treatments and drugs across a range of populations. The collection and use of real-world research and data to inform the potential use, risks, and benefits of medical products and treatments can ultimately lead to better health outcomes, particularly for those who have been underrepresented in the past.
Existing efforts to improve inclusion
Efforts to expand diversity and representation in medical research are underway in Congress. Policymakers are encouraging the incorporation of Real World Evidence (RWE) in drug development through the recent Cures 2.0 draft legislation released by Reps. Diana Degette (D-CO-1) and Fred Upton (D-MI-6). While the status quo limits us from effectively reaching underserved populations, the proposed legislation would allow studies that include RWE for some drugs after they have been approved. At the heart of this issue is a growing appreciation that the same therapy can affect different populations in different ways, which is why Cures 2.0 supports collecting data that more accurately reflects the unique experiences and needs of patients across diverse populations.
Recognizing the potential for RWE in maternal health
The lack of representative research in the field of maternal health is undeniable, and its implications are staggering. The dismal state of maternal care in the United States reflects how our health care system has failed women of color, including by not adequately studying treatment options to prevent maternal morbidity and mortality. The need for RWE is clear when you consider the persistent disparities in health outcomes that plague minority communities.
Preterm birth and its disproportionate impact on women of color is a stark illustration of the need to make progress on representative research in maternal health. Preterm birth is the second-largest contributor to infant death in America today. Despite the tremendous physical, emotional, and financial toll that preterm birth continues to take on our country — disproportionately so on women and families of color — not enough therapeutic tools currently exist to prevent it.
Today, “17P,” the only FDA-approved treatment to help reduce the likelihood of spontaneous, recurrent preterm birth in the United States is at-risk of being withdrawn from the market in all its forms, including the branded product and five generic versions. Unfortunately there is conflicting evidence from two different clinical trials, one representative of a diverse U.S. population and another studied in a largely white population in Europe. It’s not a straightforward comparison. If 17P is withdrawn, the women most affected by preterm birth, predominantly women of color, would be left without an FDA-approved treatment option.
The FDA is considering the path forward, including additional data collection through leveraging RWE from past patient use. The success of the first (approval) trial for 17P in the impacted communities signals the importance of RWE. Continued access to 17P is, at its core, a matter of health equity. Black women must not yet again be left vulnerable to a system that historically has overlooked them.
